Vertex to buy Crinetics for $10 billion, diversifying beyond cystic fibrosis

Vertex Pharmaceuticals said it will buy Crinetics Pharmaceuticals for about $10.0 billion in cash, a move that gives the cystic-fibrosis leader a bigger foothold in rare endocrine diseases and a clearer path beyond its flagship franchise. Vertex offered $85.00 a share, a 102% premium to Crinetics’ Monday close, and said the deal was unanimously approved by both boards and should close in the third quarter of 2026.

The transaction gives Vertex an already commercial product in PALSONIFY, the first once-daily oral therapy approved by the U.S. Food and Drug Administration for adults with acromegaly. Crinetics said the medicine, approved in September 2025, was recently cleared by the European Medicines Agency and is under review by other global regulators. Vertex said PALSONIFY affects an estimated 20,000 diagnosed patients in the U.S., a small market by pharmaceutical standards but one that can support premium pricing if adoption broadens.

Crinetics also brings atumelnant, which is in Phase 3 development for congenital adrenal hyperplasia. The company said June 2026 Phase 2 data showed sustained androgen reductions and allowed lower glucocorticoid supplementation, while ClinicalTrials.gov lists the late-stage CALM-CAH study as a randomized, double-blind, placebo-controlled trial in adults with classic CAH due to 21-hydroxylase deficiency. Crinetics has said classic CAH has about 17,000 addressable patients in the U.S.

For Vertex, the deal is as much about strategy as product. The company reported $12.0 billion in full-year 2025 revenue, up 9% from 2024, and said in February that non-CF products were expected to contribute $500 million or more in 2026 revenue. Last year, Vertex posted $11.02 billion in product revenue and said it wanted to broaden its revenue base, disease areas, pipeline and geographies. The Crinetics purchase extends that effort into endocrinology, adding a fifth vertical alongside cystic fibrosis, hematology, pain and renal disease.

Investors will now watch two questions closely. First is whether the overlap between Vertex’s existing portfolio and Crinetics’ endocrine pipeline stays limited enough to avoid distraction while still giving Vertex a meaningful second act. Second is regulatory risk: PALSONIFY still needs additional approvals outside the U.S., and atumelnant must carry its Phase 3 momentum through larger studies before it becomes a true revenue contributor. If both programs advance, the acquisition could meaningfully change Vertex’s growth story; if they stumble, the company will still be leaning heavily on cystic fibrosis.